Considerations for the Management and Triage of Ocular Oncology Cases during the COVID-19 Pandemic
Ocul Oncol Pathol
.
2020 Apr 21;6(3):1-4.
doi: 10.1159/000507734.
Authors
Alison H Skalet
1
2
3
4
,
Richard C Allen
5
6
,
Carol L Shields
7
,
Matthew W Wilson
8
9
10
,
Prithvi Mruthyunjaya
11
,
Dan S Gombos
12
6
13
Affiliations
1
Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
2
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
3
Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, USA.
4
Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
5
Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
6
Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
7
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
8
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
9
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
10
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
11
Ophthalmology, Stanford Byers Eye Institute, Palo Alto, California, USA.
12
The Retinoblastoma Center of Houston, Houston, Texas, USA.
13
Section of Ophthalmology, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas, USA.
PMID:
32411697
PMCID:
PMC7206351
DOI:
10.1159/000507734
No abstract available